| 1 |
Hegde M, Naliyadhara N, Unnikrishnan J, Alqahtani MS, Abbas M, Girisa S, Sethi G, Kunnumakkara AB. Nanoparticles in the diagnosis and treatment of cancer metastases: Current and future perspectives. Cancer Lett 2023;556:216066. [PMID: 36649823 DOI: 10.1016/j.canlet.2023.216066] [Reference Citation Analysis]
|
| 2 |
Yang W, Pan Q, Huang F, Hu H, Shao Z. Research progress of bone metastases: From disease recognition to clinical practice. Front Oncol 2022;12:1105745. [PMID: 36761418 DOI: 10.3389/fonc.2022.1105745] [Reference Citation Analysis]
|
| 3 |
Zhao Y, Deng X, Tan S, Zhang J, Han J, Wang X, Pei J, Li H, Deng X, Yin C, Yin D, Tian Y, Qian A. Co-Polymer Carrier with Dual Advantages of Cartilage-Penetrating and Targeting Improves Delivery and Efficacy of MicroRNA Treatment of Osteoarthritis. Adv Healthc Mater 2023;12:e2202143. [PMID: 36511367 DOI: 10.1002/adhm.202202143] [Reference Citation Analysis]
|
| 4 |
Zhai D, Wang W, Ye Z, Xue K, Chen G, Hu S, Yan Z, Guo Y, Wang F, Li X, Xiang A, Li X, Lu Z, Wang L. QKI degradation in macrophage by RNF6 protects mice from MRSA infection via enhancing PI3K p110β dependent autophagy. Cell Biosci 2022;12:154. [DOI: 10.1186/s13578-022-00865-9] [Reference Citation Analysis]
|
| 5 |
Tian Q, Lu Y, Yan B, Wu C, Chen L. Integrative Bioinformatics Analysis Reveals That miR-524-5p/MEF2C Regulates Bone Metastasis in Prostate Cancer and Breast Cancer. Computational and Mathematical Methods in Medicine 2022;2022:1-13. [DOI: 10.1155/2022/5211329] [Reference Citation Analysis]
|
| 6 |
Shen Y, Lv Y. Dual targeted zeolitic imidazolate framework nanoparticles for treating metastatic breast cancer and inhibiting bone destruction. Colloids Surf B Biointerfaces 2022;219:112826. [PMID: 36115265 DOI: 10.1016/j.colsurfb.2022.112826] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
|
| 7 |
Liu D, Cheng Y, Qiao S, Liu M, Ji Q, Zhang BL, Mei QB, Zhou S. Nano-Codelivery of Temozolomide and siPD-L1 to Reprogram the Drug-Resistant and Immunosuppressive Microenvironment in Orthotopic Glioblastoma. ACS Nano 2022. [PMID: 35549164 DOI: 10.1021/acsnano.1c09794] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 8 |
Morarasu S, Morarasu BC, Ghiarasim R, Coroaba A, Tiron C, Iliescu R, Dimofte G. Targeted Cancer Therapy via pH-Functionalized Nanoparticles: A Scoping Review of Methods and Outcomes. Gels 2022;8:232. [DOI: 10.3390/gels8040232] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 9 |
Tian Y, Zhao Y, Yin C, Tan S, Wang X, Yang C, Zhang T, Zhang X, Ye F, Xu J, Wu X, Ding L, Zhang J, Pei J, Wang X, Zhang RX, Xu J, Wang W, Filipe CD, Hoare T, Yin D, Qian A, Deng X. Polyvinylamine with moderate binding affinity as a highly effective vehicle for RNA delivery. Journal of Controlled Release 2022. [DOI: 10.1016/j.jconrel.2022.03.003] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 10 |
Shao H, Varamini P. Breast Cancer Bone Metastasis: A Narrative Review of Emerging Targeted Drug Delivery Systems. Cells 2022;11:388. [PMID: 35159207 DOI: 10.3390/cells11030388] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
|
| 11 |
Gajbhiye KR, Dhapte V, Varma S, Chaudhari BP, Gajbhiye V. Redox-responsive nanomedicine for breast cancer therapy. Targeted Nanomedicine for Breast Cancer Therapy 2022. [DOI: 10.1016/b978-0-12-824476-0.00005-x] [Reference Citation Analysis]
|
| 12 |
Cheng X, Zhao JX, Dong F, Cao XC. ARID1A Mutation in Metastatic Breast Cancer: A Potential Therapeutic Target. Front Oncol 2021;11:759577. [PMID: 34804958 DOI: 10.3389/fonc.2021.759577] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 13 |
Cheng X, Wei J, Ge Q, Xing D, Zhou X, Qian Y, Jiang G. The optimized drug delivery systems of treating cancer bone metastatic osteolysis with nanomaterials. Drug Deliv 2021;28:37-53. [PMID: 33336610 DOI: 10.1080/10717544.2020.1856225] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 4.0] [Reference Citation Analysis]
|
| 14 |
Huang Y, Guan Z, Dai X, Shen Y, Wei Q, Ren L, Jiang J, Xiao Z, Jiang Y, Liu D, Huang Z, Xu X, Luo Y, Zhao C. Engineered macrophages as near-infrared light activated drug vectors for chemo-photodynamic therapy of primary and bone metastatic breast cancer. Nat Commun 2021;12:4310. [PMID: 34262026 DOI: 10.1038/s41467-021-24564-0] [Cited by in Crossref: 39] [Cited by in F6Publishing: 37] [Article Influence: 19.5] [Reference Citation Analysis]
|
| 15 |
Vanderburgh J, Hill JL, Gupta MK, Kwakwa KA, Wang SK, Moyer K, Bedingfield SK, Merkel AR, d'Arcy R, Guelcher SA, Rhoades JA, Duvall CL. Tuning Ligand Density To Optimize Pharmacokinetics of Targeted Nanoparticles for Dual Protection against Tumor-Induced Bone Destruction. ACS Nano 2020;14:311-27. [PMID: 31894963 DOI: 10.1021/acsnano.9b04571] [Cited by in Crossref: 19] [Cited by in F6Publishing: 20] [Article Influence: 6.3] [Reference Citation Analysis]
|
| 16 |
Segaliny AI, Cheng JL, Farhoodi HP, Toledano M, Yu CC, Tierra B, Hildebrand L, Liu L, Liao MJ, Cho J, Liu D, Sun L, Gulsen G, Su MY, Sah RL, Zhao W. Combinatorial targeting of cancer bone metastasis using mRNA engineered stem cells. EBioMedicine 2019;45:39-57. [PMID: 31281099 DOI: 10.1016/j.ebiom.2019.06.047] [Cited by in Crossref: 15] [Cited by in F6Publishing: 11] [Article Influence: 3.8] [Reference Citation Analysis]
|
| 17 |
Qiu L, Ge L, Long M, Mao J, Ahmed KS, Shan X, Zhang H, Qin L, Lv G, Chen J. Redox-responsive biocompatible nanocarriers based on novel heparosan polysaccharides for intracellular anticancer drug delivery. Asian J Pharm Sci 2020;15:83-94. [PMID: 32175020 DOI: 10.1016/j.ajps.2018.11.005] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.8] [Reference Citation Analysis]
|
